FeCILL: Reimagining How We Treat the Sickest PatientsNext
Opportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute and Massachusetts General Hospital are developing a new delivery method for systemic antifungals that could help reduce negative side effects and better target the infection.
Credit: Wyss Institute at Harvard University